AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7987780
Drug: Group behavioral-cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group behavioral-cognitive therapy with imipramine
Trial: 2602607
Drug: Verapamil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil plus Isosorbide Dinitrate (120 mg verapamil + 20 mg isosorbide dinitrate)
Trial: 9514436
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg)
Trial: 793956
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with prednisone
Trial: 793956
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of prednisone
Trial: 31143396
Drug: Gel fortified
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel fortified with 0.5% chlorhexidine and 70% ethyl alcohol (in a volume ratio of 20:2:1)
Trial: 31143396
Drug: Plain non-sterile
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plain non-sterile gel
Trial: 25017624
Drug: Normal standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal standard treatment
Trial: 16580907
Drug: Cetirizine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (20 mg/d)
Trial: 16580907
Drug: Pilsicainide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilsicainide (150 mg/d)
Trial: 15288212
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg ethinylestradiol + 2 mg dienogest (30EE/DNG)
Trial: 15288212
Drug: 20 microg
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg ethinylestradiol + 2 mg dienogest (20EE/DNG)
Trial: 15288212
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg ethinylestradiol + 2 mg estradiol valerate + 2 mg dienogest (EE/EV/DNG)
Trial: 8221821
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of extended-release isradipine for 30 days
Trial: 3767522
Drug: AVP-antagonist, d(CH2)5Tyr(Me)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP-antagonist, d(CH2)5Tyr(Me) AVP, 5 micrograms/kg i.v.
Trial: 24626140
Drug: Contrast training
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast training (CT) program (isometric + plyometric), no external loads, twice a week for 12 weeks
Trial: 23647956
Drug: Telaprevir monotherapy
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir monotherapy
Trial: 23647956
Drug: Telaprevir plus
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir plus peginterferon alfa-2a and ribavirin (triple therapy)
Trial: 20133188
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for insomnia (CBT‐I)
Trial: 16283367
Drug: HRT+ (hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT+ (hormone replacement therapy)
Trial: 12557135
Drug: Low-dose growth
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose growth hormone (0.05 mg. kg(‐1). day(‐1))
Trial: 10376126
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg p.o. daily)
Trial: 8745894
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5% w/w benzoyl peroxide and 3% w/w erythromycin
Trial: 1535215
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of erythromycin and benzoyl peroxide
Trial: 1796233
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg daily x 3
Trial: 1796233
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg daily x 3
Trial: 1796233
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg daily x 7
Trial: 30114252
Drug: Surveillance cues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surveillance cues (e.g., photographs of watching eyes)
Trial: 27561827
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for 8 weeks (TG)
Trial: 28222641
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SG)
Trial: 20826250
Drug: beta-blocker utilization
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker utilization at discharge
Trial: 20826250
Drug: beta-blocker dosing
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker dosing categories at discharge
Trial: 20826250
Drug: beta-blocker dose
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker dose change between discharge and 3 weeks
Trial: 20826250
Drug: Predictors of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictors of very low beta-blocker doses
Trial: 18456521
Drug: Non-opioid analgesics
RxNorm normalized name: Non-opioid analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid analgesics (NOAs), median intake of 1325 mg/week ibuprofen-equivalents (IE) for 46 subjects using NOAs
Trial: 18456521
Drug: Non-opioid analgesics
RxNorm normalized name: Non-opioid analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid analgesics (NOAs)
Trial: 15584985
Drug: Low-dose PLT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose PLT transfusions (3 PLT units)
Trial: 15584985
Drug: Standard-dose PLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose PLT transfusions (5 PLT units)
Trial: 10859038
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin or low-molecular-weight heparin (LMWH)
Trial: 10859038
Drug: Long-term low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term low-molecular-weight heparin (LMWH)
Trial: 3707800
Drug: nalbuphine 4.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 4.5, 8, 15, 25 or 50 mg/70 kg
Trial: 3707800
Drug: morphine 3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 3, 5, 10 or 17.5 mg/70 kg
Trial: 3707800
Drug: nalbuphine (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine (highest dose)
Trial: 26169094
Drug: High-dose esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose esomeprazole (80 mg IV, then 8 mg/h continuous infusion for 3 days)
Trial: 26169094
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose esomeprazole (40 mg IV every 12 h for 72 h)
Trial: 17215611
Drug: Pelvic muscle
RxNorm normalized name: urinary incont device, pelvic muscle toner, elect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic muscle enforcement program by biofeedback and electrical stimulation for 30 minutes per session, twice a week for 6 weeks, followed by self-exercise of pelvic floor muscle (50-60 repetitions per session, 3 times a day for 6 weeks)
Trial: 9223884
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine 0.1 mg (bolus injection)
Trial: 9223884
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine 0.3 mg (continuous infusion)
Trial: 9223884
Drug: Epidural droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural droperidol 2.5 mg (bolus injection)
Trial: 9223884
Drug: Epidural droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural droperidol 5 mg (continuous infusion)
Trial: 8163613
Drug: Cefamandole (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (single injection at operative site during local anesthesia)
Trial: 3019976
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (120 mg/m2 every 4 weeks)
Trial: 3019976
Drug: Low-dose cisplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cisplatin (80 mg/m2 every 3 weeks)
Trial: 7512356
Drug: VM-26 dose
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VM-26 dose levels (60, 80, 100, 120 mg/m2/day)
Trial: 7512356
Drug: VM-26 dose
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VM-26 dose level of 120 mg/m2/day
Trial: 2893038
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of single-strand recombinant tissue plasminogen activator (rTPA) in 3 hours (n = 73)
Trial: 2893038
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of single-strand recombinant tissue plasminogen activator (rTPA)
Trial: 29504252
Drug: AZL-M/CLD 20/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL-M/CLD 20/12.5 mg
Trial: 29504252
Drug: OLM/HCTZ 20/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLM/HCTZ 20/12.5 mg
Trial: 25699397
Drug: 3DCRT (three-dimensional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3DCRT (three-dimensional conformal radiation therapy)
Trial: 20609025
Drug: Resilon filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resilon filled with immediate post space preparation leaving 5 mm of apical filling
Trial: 20609025
Drug: Resilon filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resilon filled with delayed post space preparation for 1 week leaving 5 mm of material apically
Trial: 20609025
Drug: Resilon filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resilon filled with immediate post space preparation leaving 3 mm of material apically
Trial: 20609025
Drug: Resilon filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resilon filled with delayed post space preparation for 1 week leaving 3 mm of material apically
Trial: 16046102
Drug: 1600 mg
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg SAMe (pharmaceutical dose)
Trial: 16046102
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg SAMe (nutraceutical dose)
Trial: 12122721
Drug: Somatostatin 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin 14 (S-14) infusion at a dose of 6 mg/24 h (days 1-6) and 3 mg/24 h (day 7)
Trial: 1498074
Drug: Sequential MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential MTX (300 mg/m2) and FU (900 mg/m2) with leucovorin rescue
Trial: 1498074
Drug: FU alone
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU alone (450 mg/m2/d for five days)
Trial: 1498074
Drug: Sequential MTX/FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential MTX/FU
Trial: 1498074
Drug: Sequential MTX/FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential MTX/FU and FU alone
Trial: 17198906
Drug: Aliskiren monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren monotherapy
Trial: 17198906
Drug: Aliskiren and
RxNorm normalized name: aliskiren and amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren and valsartan in combination
Trial: 17198906
Drug: Valsartan/hydrochlorothiazide (160/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/hydrochlorothiazide (160/12.5 mg)
Trial: 15389347
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 to 100 mg once daily)
Trial: 31154239
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group therapy plus an additional 10 hours of group therapy focusing on stimulant use
Trial: 31154239
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group therapy only (treatment as usual)
Trial: 28334419
Drug: Breast-conserving therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conserving therapy (BCT) with good/excellent cosmetic outcomes
Trial: 28334419
Drug: Breast-conserving therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conserving therapy (BCT) with fair/poor cosmetic outcomes
Trial: 21464685
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (12 weekly healthy lifestyle sessions based on the Diabetes Prevention Program curriculum)
Trial: 11764128
Drug: 5% NaOCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% NaOCl treatment after phosphoric acid treatment
Trial: 8329783
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg with 6‐minute lockout (n = 10)
Trial: 8329783
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg with 12‐minute lockout (n = 12)
Trial: 8329783
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg with 20‐minute lockout (n = 12)
Trial: 31578100
Drug: OnabotulinumtoxinA administered
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA administered by a specialist nurse
Trial: 31578100
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of onabotulinumtoxinA scenarios
Trial: 31176028
Drug: Scheduled-dose multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled-dose multimodal analgesia with minimal opiate supply (group A)
Trial: 31176028
Drug: Scheduled-dose multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled-dose multimodal analgesia with traditional opiate supply (group B)
Trial: 28961661
Drug: Blister packing
RxNorm normalized name: Blister Armour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blister packing medications (BP)
Trial: 22781166
Drug: Full cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full cognitive behaviour therapy (CBT)
Trial: 22781166
Drug: Partial therapy
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial therapy (attending sessions but not proceeding beyond engagement and assessment strategies)
Trial: 22781166
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (not attending sessions)
Trial: 21780853
Drug: Repaglinide plus
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide plus metformin 1 mg/500 mg t.i.d. (maximum dose, 4 mg/500 mg t.i.d.)
Trial: 21780853
Drug: Repaglinide 1
RxNorm normalized name: repaglinide 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 1 mg t.i.d. (maximum dose, 4 mg t.i.d.)
Trial: 21780853
Drug: Repaglinide plus
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide plus metformin
Trial: 18582181
Drug: Methylphenidate (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.4 mg/kg)
Trial: 18582181
Drug: Methylphenidate (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.8 mg/kg)
Trial: 18582181
Drug: Methylphenidate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (1.5 mg/kg)
Trial: 2880689
Drug: Indenolol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indenolol (30 to 120 mg)
Trial: 28397533
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy adherence assessment
Trial: 18426627
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral administration of ramosetron 0.1 mg (Group C)
Trial: 18426627
Drug: Single prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single prophylactic intravenous injection of ramosetron 0.1 mg (Group B)
Trial: 17175489
Drug: Cetrorelix 0.2
RxNorm normalized name: cetrorelix 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix 0.2 mg/day (Group 1)
Trial: 17175489
Drug: Cetrorelix 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix 0.15 mg/day (Group 2)
Trial: 14561020
Drug: HandiHaler (tiotropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HandiHaler (tiotropium 18 microg daily)
Trial: 11127249
Drug: Quinine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (oral dose)
Trial: 8865956
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin (200 IU three times a week)
Trial: 8865956
Drug: Biological markers
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological markers of alcohol consumption
Trial: 31029516
Drug: Dukoral® oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dukoral® oral cholera vaccine (administered at baseline and day 14)
Trial: 31029516
Drug: Dukoral® oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dukoral® oral cholera vaccine (administered at baseline and day 14) in P/CNI group
Trial: 31029516
Drug: Dukoral® oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dukoral® oral cholera vaccine (administered at baseline and day 14) in P/MMF group
Trial: 28614627
Drug: Multimodal cachexia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal cachexia intervention (n‐3 polyunsaturated fatty acid nutritional supplements, exercise, and anti‐inflammatory medication: celecoxib)
Trial: 22231004
Drug: Toothbrushing with
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toothbrushing with 0.12% chlorhexidine gluconate (Periogard®) mouthrinses twice a week
Trial: 11831621
Drug: Successful treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful treatment strategies for atheroma
Trial: 9758029
Drug: SUPPORT intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUPPORT intervention (n=386): specially trained nurses providing extra time to explain prognoses and treatments
Trial: 8641505
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative medical treatment
Trial: 6795050
Drug: Acute pentagastrin
RxNorm normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute pentagastrin injection in normal male subjects
Trial: 6795050
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of pentagastrin
Trial: 6795050
Drug: Intragastric administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intragastric administration of a calcium chloride solution
Trial: 29065142
Drug: MVA-B boost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-B boost (fourth dose)
Trial: 20145345
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg/day) with clopidogrel (75 mg/day)
Trial: 20145345
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/day) alone (placebo)
Trial: 17919378
Drug: Cattle encephalon
RxNorm normalized name: Oryctolagus cuniculus diencephalon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cattle encephalon glycoside and ignotin injection (20 ml after induction of anesthesia)
Trial: 15673424
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose solution
Trial: 7963387
Drug: Interpleural block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural block (IPB) with 10 ml of 1% lidocaine
Trial: 7963387
Drug: Epidural block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural block (EB) with 10 ml of 1% lidocaine
Trial: 3298360
Drug: Intravenous APSAC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous APSAC, 30 mg (n = 16)
Trial: 27629372
Drug: Medicine (medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine (medicine group)
Trial: 24961325
Drug: Neovasculogen (plasmid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neovasculogen (plasmid genetic construction containing human gene VEGF165) at a course dose of 2.4 mg
Trial: 24961325
Drug: Conventional vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional vascular therapy